SEC Company Response from TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956) (TENX) — Dec 4, 2018
TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)
Date: Dec. 4, 2018 · CIK: 0000034956 · Accession: 0001654954-18-013567
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228212
Letter
VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Tenax Therapeutics, Inc. Registration Statement on Form S-1 No. 333-228212 Request for Acceleration
Dear Mr. Regan:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tenax Therapeutics, Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-228212), so that it may be declared effective at 4:30 p.m., Eastern Time on Thursday, December 6, 2018, or as soon thereafter as is practicable.
If you have any questions, please contact me at (919) 855-2123. Thank you in advance for your assistance.
Sincerely,
/s/ Michael B. Jebsen
Show Raw Text
CORRESP 1 filename1.htm Blueprint December 4, 2018 VIA EDGAR TRANSMISSION Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0306 Attn: Ruairi Regan Division of Corporation Finance Re: Tenax Therapeutics, Inc. Registration Statement on Form S-1 No. 333-228212 Request for Acceleration Dear Mr. Regan: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tenax Therapeutics, Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-228212), so that it may be declared effective at 4:30 p.m., Eastern Time on Thursday, December 6, 2018, or as soon thereafter as is practicable. If you have any questions, please contact me at (919) 855-2123. Thank you in advance for your assistance. Sincerely, /s/ Michael B. Jebsen Michael B. Jebsen President and Chief Financial Officer cc: Margaret N. Rosenfeld Partner, Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.